FDA Approved: JAKAFI — Supplemental Application (Incyte Corporation)

View source ↗

Summary

The FDA announced a supplemental application submission for JAKAFI (ruxolitinib) by Incyte, indicating a potential supplemental approval. The filing may involve…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

SUPPL AP for JAKAFI (RUXOLITINIB)